Core Viewpoint - The synthetic biology industry is facing a critical juncture, with the entrepreneurial window closing and competition shifting towards a survival of the fittest scenario, as highlighted by the experiences of companies like Weiming Shiguang [2][16]. Group 1: Company Overview - Weiming Shiguang, a synthetic biology startup, has completed six rounds of financing and achieved a valuation of over $100 million, gaining significant attention through a partnership with L'Oréal [3][4]. - The company has over 100 clients, including major players like L'Oréal and Huaxi Biological, and has registered 158 raw materials with the National Medical Products Administration [4]. Group 2: Challenges and Market Dynamics - The company faced significant challenges during the 2022 funding crisis, where many synthetic biology firms went bankrupt, including the pioneer Amyris [5]. - The investment landscape has shifted, with a focus on practical outcomes and stable supply capabilities rather than just potential market stories, making it harder for new entrants to secure funding [16][18]. Group 3: Product Focus and Innovation - Weiming Shiguang's strategic choice to focus on the relatively unknown 17-type collagen, rather than the more established 3-type collagen, reflects a commitment to scientific potential despite market uncertainties [10][11]. - The company is also exploring the potential of plant callus extracts, which are gaining traction in new raw material registrations, indicating a forward-looking approach to product development [11]. Group 4: Future Outlook - The company aims to leverage AI technology in material design and expand its application scenarios and global channels, aspiring to become a leader in the biomanufacturing sector [19]. - The historical context of synthetic biology suggests a transformative potential similar to that of chemical synthesis in the past, with implications for health and beauty industries [20].